Skip to main content

Table 1 Characteristics of participants included in the study

From: Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue

  BPH (n = 6) OCPCa (n = 6) EPCa (n = 6) P
Age (years) 67.4 ± 3.9 59.4 ± 2.9 66.9 ± 2.3 0.140a
BMI (kg/m2) 26.5 ± 1.5 25.2 ± 1.3 26.5 ± 1.6 0.783a
Serum total PSA (ng/mL) 8.9 ± 4.7 6.7 ± 1.6 14.7 ± 3.0 0.114b
Prostate weight (g) 107.0 ± 12.9 40.8 ± 4.2 71.2 ± 9.5 0.001a, c
Serum leptin (mg/mL) 3.7 ± 1.0 7.1 ± 2.5 4.9 ± 1.8 0.453a
Combined Gleason score     
≤7 (3+4), n (%) --- 5 (83%) 4 (67%) 1.000d
≥7 (4+3), n (%) --- 1 (17%) 2 (33%)  
  1. Continuous variables are presented as mean ± SE. aANOVA for independent measures; bKruskal-Wallis test; cLSD post-hoc analysis: BPH versus organ confined PCa, P <0.0001, BPH versus extra prostatic cancer, P = 0.018, extra prostatic cancer versus organ confined PCa, P = 0.040; dFisher exact test. Median (interquartile range) values for serum total PSA: BPH, 4.7 (3.7 to 18.4) ng/mL; organ confined cancer, 5.1 (4.1 to 10.2) ng/mL; extra-prostatic cancer, 14.7 (8.3 to 21.2) ng/mL. ANOVA, analysis of variance; BMI, body mass index; BPH, benign prostatic hyperplasia; EPCa, extra prostatic cancer; OCPCa, organ confined prostate cancer; PCa, prostate cancer; PSA, prostate specific antigen.